Introduction
============

Chemotherapy is a mainstay of cancer treatment in addition to surgery, radiotherapy, and antibody-based immunotherapy. Conventional chemotherapy fails for many cancer patients due to various factors, drug resistance being one of the main reason together with severe side effects. Therefore, drug research constantly attempts to improve treatment results by the preclinical development of new drugs and the optimization of therapy regimens in the clinic.

Natural products always played an important role in cancer pharmacology ([@B44]), they are not only well-established cytotoxic anticancer drugs (e.g., anthracyclines, *Vinca* alkaloids, taxanes, camptothecins, etc.), but also valuable lead compounds for the development of novel targeted chemotherapy approaches ([@B55]; [@B15]; [@B16]). Natural products can exert synergistic interaction with other natural or synthetic drugs ([@B9]; [@B41]; [@B42]; [@B54]; [@B61],[@B62]), they can overcome drug resistance ([@B20]; [@B46]; [@B52]; [@B65]), reduce side effects of chemotherapy and stimulate the immune system ([@B34]; [@B50]).

Abnormal activation of signal transduction pathways may lead to carcinogenesis, invasion, and metastasis of tumors ([@B35]; [@B51]). Signaling pathways related to the epidermal growth factor receptor (EGFR) such as EGFR/PI3K/AKT-mTOR pathway command a unique position in cancer biology ([@B8]). Targeting those proteins led to the development of cancer therapeutics such as erlotinib and gefitinib (EGFR inhibitors), LY294002 (PI3K inhibitor), peritosine (Akt inhibitor), rapamycin and sirolimus (mTOR inhibitors), and many others.

Amplification of the EGFR gene (with a frequency of ∼50% in glioblastoma multiforme-GBM) ([@B14]) is often associated with a tumor-specific mutation encoding a truncated form of the receptor, which lacks the extracellular binding domain, known as ΔEGFR (also named de2-7EGFR or EGFRvIII) leading to ligand-independent, constitutive tyrosine kinase activity. Expression of ΔEGFR is connected with glioma cell migration, tumor growth, invasion, survival, and resistance to treatment, and correlates with decreased overall survival in GBM patients ([@B22]; [@B37]). Drug resistance mediated by EGFR is not restricted to established anticancer drugs but also occurs toward other cytotoxic compounds of natural origin. Hence, EGFR-mediated resistance may represent a general type of cellular defense mechanisms toward a broad range of toxic xenobiotics ([@B26]).

A well-known tumor suppressor gene, TP53 is one of the main guardian of normal cell proliferation by preventing cells with DNA damage to proliferate. Mutations or deletions in the TP53 gene are observed in approximately 50% of human cancers, leading to impaired tumor suppressor function ([@B56]). Proliferation of cells with DNA damage rises the risk of transferring mutations to the next generation upon loss of p53 functionality; therefore, deregulation of p53 often leads to tumor formation ([@B28]). Abnormal p53 status is also linked with drug resistance and chemotherapy failure ([@B40]).

ATP-binding cassette (ABC) transporters play crucial role to regulate absorption, distribution, metabolism, and excretion in normal tissues ([@B43]). Overexpression of certain ABC transporters such as ABCG2/BCRP and ABCB1/Pgp in tumor cells is linked with resistance to chemotherapy. P-glycoprotein (P-gp) encoded by the *ABCB1/MDR1* gene is an important mechanism of MDR and is upregulated in many clinically resistant and refractory tumors ([@B31]). Overexpression of P-gp is causatively linked to accelerated efflux of chemotherapeutic agents ([@B27]) such as doxorubicin, daunorubicin, vincristine, etoposide, colchicine, camptothecins, and methotrexate ([@B5]). For instance, P-gp-overexpressing leukemia cells involve doxorubicin resistance compared to the sensitive subline ([@B25]). BCRP is involved in the efflux of mitoxantrone, topotecan, doxorubicin, daunorubicin, irinotecan, imatinib, and methotrexate ([@B5]).

Oridonin is a diterpenoid isolated from *Rabdosia rubescens* and reveals anticancer activity *in vitro* and *in vivo* ([@B59]; [@B38]; [@B60]), but its mode of action and effect on drug resistance have not been well studied. *R. rubescens* inhibited breast cancer growth and angiogenesis ([@B49]) and overcame drug resistance in ADR/MCF-7 breast cancer cells by increasing doxorubicin accumulation ([@B36]). Therefore, it is reasonable to investigate oridonin's mode of action on MDR in more detail.

In this study, we analyzed molecular factors determining the response of tumor cells to oridonin. Various drug resistance mechanisms were investigated. We addressed three main questions:

1.  Is oridonin able to bypass resistance caused by different mechanisms such as P-gp, EGFR, p53, and BCRP? Moreover, can oridonin selectively target tumor cells rather than normal cells? To address these questions, we performed cytotoxicity assays.

2.  Are there other determinants predicting sensitivity or resistance of cancer cells to oridonin? For this reason, we performed COMPARE- and hierarchical cluster analyses of transcriptome-wide mRNA expression profiles of cancer cells.

3.  Can oridonin interact with EGFR pathway proteins? To answer this question, we applied molecular docking, MD, and Western blot.

Materials and Methods {#s1}
=====================

Cell Lines
----------

CCRF-CEM leukemia cells were cultured as previously described ([@B12]). Drug resistance of P-gp/*MDR1/ABCB1*-overexpressing CEM/ADR5000 cells was maintained in 5000 ng/mL doxorubicin ([@B29]). Breast cancer cells transduced with a control vector (MDA-MB-231-pcDNA3) or with cDNA for the breast cancer resistance protein *BCRP/ABCG2* (MDA-MB-231-BCRP clone 23) were generated and maintained as reported ([@B6]). The mRNA expression of *MDR1* and *BCRP* in the resistant cell lines has been reported ([@B10]; [@B17]). Human wild-type HCT116 colon cancer cells (p53^+/+^) as well as knockout clones (p53^-/-^) derived by homologous recombination ([@B3]) were a generous gift from Dr. B. Vogelstein and H. Hermeking (Howard Hughes Medical Institute, Baltimore, MD, United States) and cultured as described ([@B3]).

Human GBM U87MG cells transduced with an expression vector harboring an *EGFR* gene with a deletion of exons 2--7 (U87MG.ΔEGFR) has been previously reported ([@B23]). Transduced and non-transduced cell lines were kindly provided by Dr. W. K. Cavenee (Ludwig Institute for Cancer Research, San Diego, CA, United States). Human HepG2 hepatocellular carcinoma cells and AML12 normal hepatocytes were obtained from the American Type Cell Culture Collection (ATCC, United States).

Resazurin Cell Growth Inhibition Assay
--------------------------------------

The resazurin (Promega, Mannheim, Germany) reduction assay ([@B45]) was used to assess the cytotoxicity as previously described ([@B33], [@B32]). Each assay was conducted at least three times, with two replicates each. Cell viability was evaluated based on a comparison with untreated cells. IC~50~ values were determined as concentrations required to inhibit 50% of cell proliferation and were calculated from a calibration curve by linear regression using Microsoft Excel.

Molecular Docking
-----------------

The protocol for molecular docking was previously reported by us ([@B27]). An X-ray crystallography-based structure of wild-type Akt2 kinase domain (PDB ID: 3E87), EGFR (PDB ID: 1M17), mTOR (PDB ID: 4JSP), STAT3 DNA-binding domain, and VEGFR1 (PDB ID: 3HNG) were obtained from Protein Data Bank^[1](#fn01){ref-type="fn"}^. Homology model of STAT3 DNA-binding domain was created by us using MODELLER 9.11 ([@B13]; [@B53]) and a Swiss-MODEL structure assessment tool^[2](#fn02){ref-type="fn"}^ based on the wild-type structure (PDB ID: 1BG1) as template. In order to assess the effect of an Akt2 mutation and EGFR mutation on oridonin binding, one point mutation-R274H on Akt2 was selected which has been shown to be critical for phosphatase resistance and keeping the phosphorylated status on Akt2 ([@B4]) and one point mutation-T790M on EGFR which has been shown to cause resistance to EGFR tyrosine kinase inhibitors ([@B64]). Homology model of R274H mutant Akt2 kinase domain was created in the same manner by using wild-type Akt2 kinase domain as template. T790M-mutant EGFR structure is available in PDB database (PDB ID: 5XDK). A grid box was then constructed to define docking spaces in each protein according to their pharmacophores. Docking parameters were set to 250 runs and 2,500,000 energy evaluations for each cycle. Docking was performed three times independently by Autodock4 and with AutodockTools-1.5.7rc1 ([@B39]) using the Lamarckian Algorithm. The corresponding lowest binding energies and pKi were obtained from the docking log files (dlg). Mean ± SD of binding energies were calculated from three independent docking. Visual Molecular Dynamics (VMD) was used to depict the docking poses of oridonin and the inhibitors for each target protein.

Molecular Dynamics
------------------

Lowest binding energy conformation of oridonin on Akt2 kinase domain prior to molecular docking analyses was picked to create ligand--protein complex structure for the MD simulations. QwikMD tool ([@B47]) was used to perform 15 ns MD simulations after the equilibration of the protein--ligand complex. Stability of the docking pose was evaluated by root mean square deviation (RMSD) distance of the conformation throughout the MD simulation with the starting conformation. Total energy of the ligand--protein complex was calculated as well.

Western Blot
------------

In order to evaluate the effect of oridonin on EGFR pathway proteins and validate the *in silico* results, varying concentrations of oridonin (IC~50~/4, IC~50~/2, IC~50~, 2xIC~50~, and 4xIC~50~), determined after the cytotoxicity test on U87MG*.ΔEGFR* cell line, were applied in a similar way as described previously ([@B48]). Briefly, 1 million cells per well were seeded in 12-well plate, next day treatment with oridonin was performed, total protein were extracted after 24 h. The following primary antibodies (Cell Signaling Technology, Frankfurt, Germany) were used: anti-rabbit EGFR, anti-rabbit phosphorylated EGFR (Tyr1068) (1:1000), anti-rabbit STAT3, anti-mouse phosphorylated STAT3 (Tyr705) (1:1000), anti-rabbit Akt, anti-rabbit phosphorylated Akt (Ser473) (1:1000), and anti-rabbit β-actin (1:2000).

COMPARE and Hierarchical Cluster Analyses
-----------------------------------------

The microarray-based mRNA expression values of genes of interest and log~10~IC~50~ values for oridonin of 49 tumor cell lines were selected from the NCI database^[3](#fn03){ref-type="fn"}^. The COMPARE analyses were performed to produce rank-ordered lists of genes expressed in the NCI cell lines. The methodology has been previously described in detail ([@B57]). Briefly, every gene of the NCI microarray database was ranked for similarity of its mRNA expression to the log~10~IC~50~ values for oridonin based on Pearson's rank correlation test. To derive COMPARE rankings, a scale index of correlations coefficients (*R*-values) was created. CIM miner software was used to perform the hierarchical clustering and heat map analysis^[4](#fn04){ref-type="fn"}^.

Statistical Analyses
--------------------

Results were represented as mean ± SD. Student's *t*-test was performed in order to evaluate the statistical significance with two tails and unequal variance. Experiments with *p*-values lower than 0.05 were accepted as statistically significant.

Results
=======

Response of Drug-Resistant Tumor Cell Lines Toward Oridonin
-----------------------------------------------------------

Cytotoxicity of oridonin and doxorubicin toward sensitive and drug-resistant cancer cell lines and normal cells were determined by the resazurin reduction assay (**Table [1](#T1){ref-type="table"}**). The recorded IC~50~ values ranged from 1.65 (toward CCRF-CEM cells) to 34.68 μM (against HCT116P53^-/-^ cells) for oridonin and from 0.24 (toward CCRF-CEM cells) to 195.12 μM (against HCT116P53^-/-^ cells) for doxorubicin. The degree of resistance of resistant cells was calculated by dividing the IC~50~ value of this cell line by the IC~50~ value of the parental sensitive cells (**Table [1](#T1){ref-type="table"}**). Oridonin was tested against multidrug-resistant P-gp (*MDR1*/*ABCB1*)-overexpressing CEM/ADR5000 cells and drug-sensitive parental CCRF-CEM cells using a resazurin assay. Although a weak cross-resistance of the CEM/ADR5000 cells was obtained (5.17-fold), this was much lower than that obtained with doxorubicin (975.60-fold). In another cell model for MDR, we compared the cytotoxicity of oridonin toward MDA-MB-231 cells transfected with *BCRP/ABCG2* and cells transfected with pcDNA control vector. The *BCRP* transfectants were 1.61-fold more resistant to oridonin than their sensitive counterparts. The activities of oridonin in knockout HCT116 (p53^-/-^) cells and their sensitive wild-type HCT116 (p53^+/+^) cells were also compared. *TP53*-knockout cells were cross-resistant to this compound than the *TP53* wild-type cells (degree of resistance: 1.92). However, the degree of resistance was slightly less resistant than that obtained with doxorubicin (2.84-fold). Interestingly, U87MG cells transfected with a deletion-activated *EGFR* cDNA were considerably more sensitive to oridonin than their wild-type counterpart (degree of resistance: 0.88). Normal AML10 hepatocytes were more resistant to oridonin than HepG2 hepatocellular carcinoma cells, indicating that the cytotoxic effects of oridonin may display tumor specificity at least to some extent.

###### 

Cytotoxicity of oridonin and doxorubicin toward sensitive and drug-resistant cancer cell lines and normal cells as determined by the resazurin reduction assay.

  Cell lines            Compounds, IC~50~ values in μM, and degree of resistance^a^ (in bracket)                             
  --------------------- -------------------------------------------------------------------------- ------------------------- ---------------------------
  CCRF-CEM              1.65 ± 0.14                                                                0.24 ± 0.02               
  CEM/ADR5000           8.53 ± 0.77 (5.17)                                                         195.12 ± 14.30 (975.60)   P-gp
  MDA-MB231             6.06 ± 0.71                                                                1.10 ± 0.01               
  MDA-MB231/*BCRP*      9.74 ± 1.04 (1.61)                                                         7.83 ± 0.01 (7.11)        BCRP
  HCT116 (*p53^+/+^*)   18.03 ± 1.61                                                               1.43 ± 0.02               
  HCT116 (*p53^-/-^*)   34.68 ± 2.98 (1.92)                                                        4.06 ± 0.04 (2.84)        p53
  U87MG                 17.37 ± 1.16                                                               1.06 ± 0.03               
  U87MG*.ΔEGFR*         15.34 ± 1.67 (0.88)                                                        6.11 ± 0.04 (5.76)        EGFR
  AML12                 \>109.76                                                                   \>73.59                   
  HepG2                 25.71 ± 2.11 (\<0.23)                                                      1.41 ± 0.12 (\<0.04)      Tumor versus normal cells

Mean values ± SD of each three independent experiments with each six parallel measurements are shown.

a

The degree of resistance was determined as the ratio of IC

50

value of the resistant/IC

50

-sensitive cell line. N.a., not applicable.

Molecular Docking and Molecular Dynamics
----------------------------------------

Oridonin interacts with EGFR signaling pathway proteins, as can be seen in **Figure [1](#F1){ref-type="fig"}**. Comparable binding energies and docking poses were observed for Akt2 and STAT3 proteins with those of known inhibitors \[GSK690693 ([@B21]) for Akt2 and NSC74859 ([@B63]) for STAT3\]. ATP-binding domain of Akt2 consists of the following residues: Leu158, Val166, Ala179, Val213, Met229, Tyr231, Met282, Thr292, Phe294, Ala322, and Phe439 ([@B24]). Oridonin interacts with Val166 and forms hydrogen bond with Thr292 implying its inhibitory effect.

![Molecular docking studies of oridonin and known inhibitors on proteins involved in EGFR signaling pathway. Proteins have been represented in new cartoon format with different colors, while oridonin was represented in yellow. **(A)** Docking poses in to the pharmacophore of Akt2 kinase domain (PDB code: 3E87 in green cartoon representation). GSK690693 was represented in blue. **(B)** Docking poses in to the pharmacophore of EGFR tyrosine kinase domain (PDB code: 1M17 in gray cartoon representation). Gefitinib was represented in green and erlotinib was represented in blue. **(C)** Docking poses in to the pharmacophore of mTOR (PDB code: 4JSP in orange representation). Sirolimus was represented in blue. **(D)** Docking poses in to the pharmacophore of STAT3 DNA-binding domain (homology model created by using the template PDB code: 1BG1 in pink cartoon representation). NSC74859 was represented in blue. **(E)** Docking poses in to the pharmacophore of VEGFR1 (PDB code: 3HNG in black cartoon representation). Axitinib was represented in blue.](fphar-09-00355-g001){#F1}

Oridonin can still bind with comparable binding energies on mutant Akt2 and EGFR as can be seen in **Table [2](#T2){ref-type="table"}**. Interestingly, oridonin interacts with EGFR-T790M significantly stronger than to wild-type EGFR (-6.633 vs. -5.160 kcal/mol). pKi is significantly lower as well (14.283 vs. 166.310 μM). Gefitinib binds to EGFR-T790M significantly weaker than to wild-type EGFR (-7.773 vs. -8.307 kcal/mol).

###### 

Comparison of binding energies of oridonin and known inhibitors on wild-type and mutant Akt2 and EGFR (LBE, kcal/mol; pKi, μM).

              EGFR wt           EGFR-T790M         LBE *p*-value       pKi *p*-value                
  ----------- ----------------- ------------------ ------------------- ------------------- -------- --------
  Oridonin    -5.160 ± 0.106    166.310 ± 30.323   -6.633 ± 0.202      14.283 ± 5.300      \<0.05   \<0.05
  Erlotinib   -7.537 ± 0.267    3.183 ± 1.222      -7.547 ± 0.371      3.293 ± 1.645       \>0.05   \>0.05
  Gefitinib   -8.307 ± 0.114    0.820 ± 0.161      -7.773 ± 0.196      2.070 ± 0.615       \<0.05   \>0.05
                                                                                                    
              **Akt2 wt**       **Akt2-R274H**     **LBE *p*-value**   **pKi *p*-value**            
              **LBE**           **pKi**            **LBE**             **pKi**                      
                                                                                                    
  Oridonin    -7.560 ± 0.035    2.873 ± 0.188      -7.253 ± 0.023      4.830 ± 0.166       \<0.05   \<0.05
  Gsk690693   -10.970 ± 0.026   0.091 ± 0.004      -10.930 ± 0.010     0.097 ± 0.002       \>0.05   \>0.05

The docking pose of oridonin on Akt2 kinase domain was used as starting conformation for the MD simulation. As can be seen in **Figure [2](#F2){ref-type="fig"}**, the LBE conformation of oridonin was stable, since the RMSD value was below 1 Å (0.567 ± 0.117) throughout 15 ns simulation.

![Oridonin--Akt2 kinase domain MD simulation. **(A)** Number of H-bonds between oridonin and Akt2. **(B)** RMSD of oridonin aligned with the LBE conformation acquired after molecular docking calculations. **(C)** Van der Waals, total energy, bond energy of oridonin--Akt2 complex. **(D)** Representative screenshots from the MD simulation.](fphar-09-00355-g002){#F2}

Western Blot
------------

In order to validate the *in silico* analyses, the phosphorylation status of EGFR signaling proteins as parameter of their activation during signal transduction was investigated. Oridonin revealed a dose-dependent inhibition of Akt and STAT3 phosphorylation supporting the *in silico* analyses, but no change in EGFR phosphorylation was observed (**Figure [3](#F3){ref-type="fig"}**). There was no change at the total Akt, EGFR, and STAT3 protein levels.

![Western blot analysis of oridonin on EGFR pathway proteins. The effects of oridonin on phosphorylation of ΔEGFR, STAT3, and Akt were evaluated. Bands were normalized to β-actin in order to obtain numerical values (mean ± SEM of three independent experiments). Total EGFR, STAT3, and Akt protein levels are also shown. A representative blot is shown and statistical analysis was done by paired Student's *t*-test. ^∗∗^*p* \< 0.01, *^∗^p* \< 0.05.](fphar-09-00355-g003){#F3}

Pharmacogenomics
----------------

We investigated the transcriptome-wide RNA expression using COMPARE analysis and mined the database of the NCI by correlating the mRNA expression data with the log~10~IC~50~ values for oridonin. This is a hypothesis-generating bioinformatical approach allowing to find novel putative molecular determinants of cellular response to oridonin. The scale rankings of genes obtained by COMPARE computation were subjected to Pearson's rank correlation tests. The thresholds for correlation coefficients were *R* \> 0.50 for direct correlations and *R* \< -0.50 for inverse correlations. As shown in **Table [3](#T3){ref-type="table"}**, the identified genes can be assigned to different functional groups such as apoptosis regulation (*CARD8*, *ANXA5*), transcriptional and protein synthesis (*FUBP1*, *RFXAP*, *CELF2*, *TWF1*, *COQ9*), DNA repair and maintenance (*RAD51C*, *BLM*), signal transduction (*PRKXP1*, *SRPK1*, *GNG12*, *IL6ST*, *PTPRK*, *MET*), cell cycle regulation (*MND1*, *PDS5B*, *PHF8*), transport functions (*ABCC5*), cellular energy regulation (*PKM2*), cell adhesion (*LAMB1*, *ADAM9*), and ubiquitination (*USP44*).

###### 

Correlation of constitutive mRNA expression of genes identified by COMPARE analyses with log~10~IC~50~ values of oridonin.

  COMPARE coefficient   Experiment ID   GB accession   Gene symbol   Name                                                                   Function
  --------------------- --------------- -------------- ------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------
  0.717                 GC158023        AI652861       *CELF2*       CUGBP, Elav-like family member 2                                       Pre-mRNA alternative splicing, mRNA translation, and stability
  0.705                 GC80864         AI983986       *PRKXP1*      Protein kinase, X-linked, pseudogene 1                                 Protein kinase homologous to *Drosophila* DC2 kinase pseudogene 1
  0.681                 GC32017         AB020630       *PPP1R16B*    Protein phosphatase 1, regulatory (inhibitor) subunit 16B              Regulator of pulmonary endothelial cell (EC) barrier function
  0.665                 GC186446        NM_014959      *CARD8*       Caspase recruitment domain family, member 8                            Inhibitor of NF-κ-B activation
  0.664                 GC31918         AF029670       *RAD51C*      RAD51 homolog C (*S. cerevisiae*)                                      Homologous recombination (HR) DNA repair pathway
  0.662                 GC35837         Z25535         *NUP153*      Nucleoporin 153 kDa                                                    DNA-binding subunit of the nuclear pore complex (NPC)
  0.662                 GC78746         AI927080       *HDHD2*       Haloacid dehalogenase-like hydrolase domain containing 2               Hydrolase activity
  0.656                 GC163915        AL036840       *FUBP1*       Far upstream element (FUSE)-binding protein 1                          Regulator of MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter
  0.655                 GC30354         AB023139       *KIAA0922*    KIAA0922                                                               Not available
  0.654                 GC169231        AW249934       *PHF8*        PHD finger protein 8                                                   Cell cycle progression, rDNA transcription, and brain development
  0.653                 GC100782        X78817         *ARHGAP4*     Rho GTPase activating protein 4                                        Inhibitor of stress fiber organization
  0.652                 GC172537        BC006312       *CROCCL1*     Ciliary rootlet coiled-coil, rootletin-like 1                          Not available
  0.652                 GC182282        NM_003137      *SRPK1*       SRSF protein kinase 1                                                  Phosphorylation of SR splicing factors and regulation of splicing
  0.651                 GC75737         AI815763       *ABCC5*       ATP-binding cassette, sub-family C (CFTR/MRP), member 5                Multispecific organic anion pump for nucleotide analogs
  0.65                  GC46177         AA542845       *MND1*        Meiotic nuclear divisions 1 homolog (*S. cerevisiae*)                  Homologous chromosome pairing, cross-over, and intragenic recombination during meiosis
  0.648                 GC152371        AF061734       *DTNBP1*      Dystrobrevin-binding protein 1                                         Biogenesis of lysosome-related organelles (LRO), such as platelet dense granules and melanosomes
  0.647                 GC37727         U42031         *FKBP5*       FK506-binding protein 5                                                Complexation with heterooligomeric progesterone receptor, HSP90, and TEBP
  0.645                 GC44551         AA448146       *USP44*       Ubiquitin-specific peptidase 44                                        Deubiquitinase that prevents premature anaphase onset in the spindle assembly checkpoint
  0.642                 GC33552         U39817         *BLM*         Bloom syndrome, RecQ helicase-like                                     DNA replication and repair
  0.64                  GC72681         AI742868       *RFXAP*       Regulatory factor X-associated protein                                 Part of the RFX complex that binds to the X-box of MHC II promoters
  -0.692                GC18026         AA004918       *LAMB1*       Laminin, β1                                                            Attachment, migration, and organization of cells into tissues during embryonic development
  -0.667                GC16842         AA025336       *SPATS2L*     Spermatogenesis-associated, serine-rich 2-like                         Not available
  -0.659                GC9768          AA047421       *GNG12*       Guanine nucleotide-binding protein (G protein), γ12                    Modulator or transducer in transmembrane signaling systems
  -0.645                GC18754         AA036724       *CAV2*        Caveolin 2                                                             Regulation of G-protein α-subunits
  -0.642                GC10289         AA053017       *ANXA5*       Annexin A5                                                             Bloodvanticoagulant protein that inhibits the thromboplastin-specific complex
  -0.64                 GC9921          AA045041       *TWF1*        Twinfilin, actin-binding protein, homolog 1 (*Drosophila*)             Inhibitor of actin polymerization likely by sequestering G-actin
  -0.623                GC18611         AA034024       *RAI14*       Retinoic acid induced 14                                               Not available
  -0.617                GC15762         W47533         *ADAM9*       ADAM metallopeptidase domain 9                                         Cell--cell or cell--matrix interactions
  -0.615                GC13860         H85457         *IL6ST*       Interleukin 6 signal transducer (gp130, oncostatin M receptor)         Signal-transducing molecule
  -0.613                GC10564         T72607         *PDS5B*       PDS5, regulator of cohesion maintenance, homolog B (*S. cerevisiae*)   Regulator of sister chromatid cohesion in mitosis which stabilizes cohesin complex association with chromatin
  -0.612                GC18739         AA035170       *TICAM2*      Toll-like receptor adaptor molecule 2                                  Regulator of the MYD88-independent pathway during the innate immune response to LPS
  -0.607                GC9920          AA045034       *OSTM1*       Osteopetrosis-associated transmembrane protein 1                       Osteoclast and melanocyte maturation and function
  -0.605                GC174276        BE908217       *ANXA2*       Annexin A2                                                             Calcium-regulated membrane-binding protein
  -0.599                GC180243        NM_000445      *PLEC*        Plectin                                                                Linker of intermediate filaments with microtubules and microfilaments and anchor of intermediate filaments to desmosomes or hemidesmosomes
  -0.599                GC33491         L77886         *PTPRK*       Protein tyrosine phosphatase, receptor type, K                         Negative regulator of EGFR signaling pathway
  -0.597                GC89723         M26252         *PKM2*        Pyruvate kinase, muscle                                                Transfer of a phosphoryl group from phosphoenolpyruvate (PEP) to ADP to generate ATP
  -0.59                 GC13104         R97218         *MET*         Met proto-oncogene (hepatocyte growth factor receptor)                 Signal transducer from the extracellular matrix into the cytoplasm
  -0.585                GC187142        NM_016639      *TNFRSF12A*   Tumor necrosis factor receptor superfamily, member 12A                 Angiogenesis and proliferation of endothelial cells
  -0.584                GC14757         N62737         *MFAP3L*      Microfibrillar-associated protein 3-like                               Not available
  -0.581                GC18658         AA034910       *COQ9*        Coenzyme Q9 homolog (*S. cerevisiae*)                                  Biosynthesis of coenzyme Q

The mRNA expression values of all NCI cell lines for the genes listed in **Table [3](#T3){ref-type="table"}** were subsequently subjected to agglomerative hierarchical cluster analysis, in order to find out, whether clusters of cell lines could be identified with similar behavior after exposure to oridonin. The dendrogram of the cluster analysis showed three clusters (**Figure [4](#F4){ref-type="fig"}**). As a next step, the log~10~IC~50~ values for oridonin, which were not included in the cluster analysis, were assigned to the corresponding position of the cell lines in the cluster tree. The distribution among the clusters was significantly different from each other as determined by Chi-square test (*p*-value = 0.0014). Cluster 1 contained in its majority of cell lines resistant to oridonin, whereas Cluster 3 contained in its majority sensitive ones (Cluster 1: 17 resistant and 7 sensitive; Cluster 2: 8 resistant and 8 sensitive; Cluster 3: 0 resistant and 9 sensitive).

![Heat map obtained by hierarchical cluster analysis from microarray-based mRNA expression profiles of the genes shown in **Table [3](#T3){ref-type="table"}** correlating with cellular responsiveness to oridonin. The analysis shows the clustering of 49 NCI tumor cell lines.](fphar-09-00355-g004){#F4}

Discussion
==========

Oridonin is a diterpenoid isolated from *R. rubescens* with previously reported anticancer activity. It targets PI3K/Akt pathway causing G2/M arrest in prostate cancer cells ([@B38]). Oridonin also targets Notch signaling leading to inhibition of breast cancer progression ([@B58]). According to the literature, 4 μg/mL or 10 μM is the upper IC~50~ limit considered for a promising cytotoxic compound after incubation for 48 and 72 h ([@B1]; [@B2]; [@B30]). In the present work, oridonin displayed IC~50~ values (\<10 μM) within this threshold value toward four tested cancer cell lines as determined by resazurin assay. These data show the antiproliferative potential of oridonin against drug-sensitive and -resistant cancer cell lines since identification of compounds able to overcome MDR is an attractive strategy in drug research ([@B7]; [@B19]; [@B18]). Interestingly, the resistant U87MG.ΔEGFR cells were even more sensitive to oridonin than their corresponding sensitive counterparts (U87MG cells). If cross-resistance was obtained, the degree or resistance was lower in all cases than that of the reference compound, doxorubicin. This suggests that oridonin could be explored further to develop a cytototoxic drug to combat MDR phenotypes.

Overexpression of P-gp, a broad spectrum drug transporter, leads to the efficient extrusion of a large number of established anticancer drugs and cytotoxic natural products out of cancer cells. This is the main reason, why tumors with P-gp overexpression exert a MDR phenotype limiting the success of established drugs. Therefore, it was a pleasing result that the expression of P-gp/*MDR1* in the NCI cell line panel did not correlate with cellular response to oridonin, which implies that P-gp does not confer resistance to oridonin. In addition, multidrug-resistant CEM/ADR5000 cells with overexpression of various ABC transporters including P-gp/*MDR1* (400-fold) ([@B25]) revealing high degrees of resistance to well-known anticancer drugs such as doxorubicin (1036-fold), vincristine (613-fold), docetaxel (435-fold), and many others ([@B11]) were even slightly more sensitive to oridonin than the parental, wild-type, drug-sensitive CCRF-CEM tumor cells. It can be speculated that oridonin successfully kills otherwise unresponsive, multidrug-resistant tumors.

Oridonin revealed comparable binding energies to EGFR pathway proteins as the known inhibitors. It shares the same docking pose with GSK690693 on Akt2 and NSC74859 on STAT3, implying the inhibitory potential of oridonin toward Akt2 and STAT3. MD study revealed that oridonin docking pose on Akt2 is stable throughout the simulation with a relatively small RMSD deviation (\<1 Angström). In order to validate the *in silico* findings and further evaluate the mode of action of oridonin, western blot experiments for the EGFR pathway proteins regarding their phosphorylation status upon oridonin treatment were performed. Results implied that cytotoxicity of oridonin is dependent on the EGFR pathway influence.

Various other resistance factors in addition to EGFR and P-gp determine the success rate of chemotherapy. In order to achieve a deeper understanding of drug response determinant mechanisms, microarray technology is widely used. This methodology is especially helpful to identify potential mechanisms of novel, still incompletely understood cytotoxic compounds. For this purpose, we performed COMPARE and hierarchical cluster analyses of transcriptome-wide, microarray-based mRNA expression of the NCI cell line panel. The expression of the genes identified via COMPARE analyses determined cellular response to oridonin in this panel of cell lines.

Despite P-gp expression was not correlated to oridonin resistance, our COMPARE analysis revealed that another member of ABC superfamily, i.e., ABCC5, was a molecular determinant to mediate resistance to oridonin in the NCI cancer cell line panel. In this context, it is worth to mention that a member of the ABC sub-family C, ABCC1 (multidrug protein 1, MRP1), which is known to confer MDR phenotype differs from that one caused by P-gp (ABCB1/MDR1) and BCRP/ABCG2 ([@B7]).

In conclusion, oridonin targeted various resistance mechanisms and inhibited Akt2 and STAT3 phosphorylation. The resistance and sensitivity genes identified may be helpful for the development of personalized therapy approaches, as their expression in an individual patient may suggest potentially successful oridonin treatment in the future. However, further preclinical and clinical studies are required to assess the therapeutic potential of oridonin for cancer therapy.
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